In general, the vaccine market is largely perceived negatively as a low-profit venture owing to the domination of top five companies, namely, Sanofi (France), Glaxo Smithkline (U.K.), Merck (U.S.), Pfizer (U.S.), and Novartis (Switzerland). Furthermore, a strong patent portfolio and the need for large investments towards vaccine development have limited the scope of entry for new companies.
The vaccine market is analyzed both in terms of qualitative (technological) and quantitative (revenue) perspectives. The technological analysis includes a discussion on different classes of vaccines, vaccine adjuvants, and commercially available products. The market revenue analysis includes market segmentation and the expected market position by 2022, with the projected growth rate.
The vaccine market is classified by technology class, types, end users, disease indication, and geography. The details on the emerging approaches to vaccine development such as reverse vaccinology, personalized vaccinomics, and systems vaccinomics are discussed. Furthermore, key research centers, with their critical areas of research in the vaccine space, have been provided.
An overview of regulations across various geographical regions has been covered. The complete value chain of the vaccine market is schematically represented and the significance of each stakeholder has been briefed.
Apart from the technological and market analysis, the investor climate has been assessed by tracking the complete investor network and collecting data on funds/grants and investments made towards vaccine development. Insights on current and future technological investment trends have also been discussed.
A large number of potential therapeutic and preventive vaccine candidates addressing various diseases which are in the pipeline are listed with their current status in clinical trials.
The adoption and developmental potential of the vaccine technology market has been discussed on a geographic basis, namely, North America, Europe, Asia, and the Rest of the World, by taking select countries that are poised to have a greater market value during the forecast period.
In brief, this research report provides:
A detailed description of the global technology developments and evolving trends in the vaccine field with key prominence on research innovations, collaborative efforts, and investments for vaccines.
A close view on the therapeutic vaccines for various diseases by providing details and status of current vaccines in the pipeline.
An impact analysis of the major drivers and restraints influencing the adoption and growth of the vaccine market during the period of 2013 to 2022.
Porters five forces analysis and GAP analysis.
The global market forecast for 2013 - 2022, including demand side analysis and strategic recommendations for technology/product developers.
Competitive landscape tracking industry activities such as mergers, acquisitions, partnerships, collaborations, and strategic agreements within the vaccine market. Intellectual property strength analysis based on the number of patents filed by the top five players within the vaccine market that gives an insight into prominent activities and global leaders of the industry.
Scope of the Report
This research report categorizes the global vaccine market into technology class, types, end users, disease indication, and geography. Each segment is further broken down by geography, with exhaustive revenue analysis for 2012 and 2013, as well as the forecast up to 2022.
Global Vaccine Market, by Technology Class
Live
Toxoid
Conjugate
Sub-Unit
Recombinant Vector Vaccines
DNA Vaccines
Synthetic Vaccines
Dentritic Vaccines
Global Vaccine Market, by Types
Preventive
Therapeutic
Global Vaccine Market, by End Users
Pediatric
Adult
Global Vaccine Market, by Disease Indication
Infectious Diseases
Cancer
Allergies
Others
Global Vaccine Market, by Geography
North America
Europe
Asia-Pacific
Rest of the World (RoW)
No comments:
Post a Comment